Why Some EMS Devices Feel Stronger but Perform Worse Over Time
About the Authors
Bertica M. Rubio, M.D.
Medical Director, Antiaging Regenerative Medicine Clinic | Board-Certified Physician | Dartmouth Medical School
Dr. Bertica M. Rubio is a board-certified physician and Medical Director of the Antiaging Regenerative Medicine Clinic in Redlands, California. She earned her Bachelor of Science degree from Loyola Marymount University and her Doctor of Medicine from Dartmouth Medical School (Geisel School of Medicine). She completed her pediatrics residency at UC Irvine Medical Center.
With decades of clinical experience, Dr. Rubio specializes in age management medicine, regenerative medicine, wound healing, and growth factor therapies. Her practice integrates evidence-based medical science with advanced aesthetic and regenerative treatments, helping patients achieve optimal health and youthful vitality.
Dr. Rubio is passionate about educating patients on the science behind skincare, facial rejuvenation, and non-invasive technologies like EMS (Electrical Muscle Stimulation) for facial toning. Her articles for PureLift LAB combine rigorous medical knowledge with practical guidance for achieving real, lasting results.
Andrew Conrad Barile, PT, DPT
Doctorate of Physical Therapy (DPT), Licensed Physical Therapist (PT)
Dr. Andrew Conrad Barile is a Doctor of Physical Therapy and the CEO and Founder of Xtreem Pulse LLC. He earned his Doctorate in Physical Therapy from Daemen College and brings over two decades of clinical and entrepreneurial experience in pediatric physical therapy, craniosacral therapy, and medical device innovation. His deep understanding of human anatomy, muscle physiology, and therapeutic technology provides invaluable science-backed approach to facial rejuvenation and anti-aging solutions.
Daniel Grinberg, MD, FACS
Board-Certified Otolaryngologist & Head and Neck Surgeon | Fellow, American College of Surgeons | Assistant Clinical Professor, Mount Sinai School of Medicine
Daniel Grinberg, MD, FACS is a Board-Certified Otolaryngologist and Head & Neck Surgeon at ENT and Allergy Associates in West Nyack, NY. He earned his medical degree from Columbia University College of Physicians and Surgeons, completed his Otolaryngology residency at New York University Medical Center, and serves as Assistant Clinical Professor at Mount Sinai School of Medicine. He is a Fellow of both the American College of Surgeons and the American Academy of Otolaryngology.
Dr. Grinberg's head-and-neck surgical perspective brings PureLift LAB readers a wider clinical lens — connecting at-home EMS practice to the underlying medical anatomy with the same scientific rigor we apply to every device specification.
Prof. Dr. med. Ivo Buschmann
Chair of Angiology, Medizinische Hochschule Brandenburg | Clinic Director, University Clinic for Angiology, Brandenburg University Hospital | Former Senior Consultant, Charité Universitätsmedizin Berlin
Prof. Dr. med. Ivo Buschmann is Chair of Angiology at the Medizinische Hochschule Brandenburg Theodor Fontane (MHB) and Clinic Director of the University Clinic for Angiology at the Brandenburg University Hospital. He completed his medical training at the University of Hamburg, served as a Max-Planck Society Fellow at the Max-Planck-Institute for Heart and Lung Research, and held senior consultant positions at the Charité Universitätsmedizin Berlin Campus Virchow before being appointed Chair at MHB in 2016.
Prof. Buschmann is one of Europe's leading authorities on arteriogenesis — the flow-driven growth and remodeling of blood vessels — with more than 150 peer-reviewed publications and several US and EU patents on devices that stimulate collateral blood vessel growth through controlled shear-rate therapy. His research connects mechanical and electrical stimulation to vascular adaptation, microcirculation, and tissue perfusion.
Prof. Buschmann's contributions bring PureLift LAB readers a vascular-biology perspective that complements our existing clinical, physical-therapy, and surgical-anatomy authorship — explaining how EMS stimulation engages not only facial muscles but also the microcirculation that supplies them, and why smart delivery matters at the level of blood flow as much as muscle contraction.
Share
Spend ten minutes on the EMS facial device side of social media and you will encounter the same review pattern repeatedly. A user receives a new device. They run their first session. They report it as "intense," "powerful," "I can really feel it working." Two months later, the same user is back, less enthusiastic, posting that the device "just doesn't feel like it used to." Nothing about the device has changed. The user's expectations haven't shifted. What has changed is the muscle's response to a stimulation pattern that hasn't varied. This article makes the case — grounded in published NMES research — that some EMS devices are engineered to feel impressive at session 1 and underperform at session 30, and the architectural difference that produces the divergence is well-documented.
What "feels stronger" actually measures
The first thing to disentangle is what "stronger sensation" is signaling. Sensation is what nerves report. Effectiveness is what muscles do. The two are correlated but not equivalent.
A waveform that lands sharply at the surface produces strong sensory-nerve activation — the sharp, prickly, "I really feel this" experience that consumer reviews equate with power. The same waveform may or may not be driving a strong muscle contraction underneath. If the operating frequency is in a band that excites surface nerves but doesn't efficiently engage motor neurons, sensation can be high while contraction is low. The user feels intensity. The muscle barely responds.
This is part of why the cleanest predictor of long-term effectiveness in an EMS device is not how strong the first session feels. It is how the device behaves at session 20, session 50, session 100 — once the novelty has faded and the muscle has been given enough exposure to the waveform for adaptation effects to compound or not compound.
What the research says happens with fixed-frequency devices
Downey, Bellman, Sharma, Wang, Gregory, and Dixon (2011), published in Muscle & Nerve, ran the cleanest available comparison: fixed-frequency stimulation versus varied-frequency stimulation in NMES, measuring how long the muscle continued to produce target contractions before failing. The finding, in their words: "Constant high-frequency stimulation protocols produce more fatigue than constant low-frequency stimulation protocols, even at matched force levels, and that varied-frequency protocols have better performance than constant-frequency protocols."
The numbers are concrete. In their healthy-subject quadriceps protocol, constant-frequency stimulation produced mean Successful Run Times of about 60–100 seconds. Varied-frequency stimulation produced mean SRTs of 165–190 seconds — roughly 60–180% longer before the muscle stopped responding effectively. "Mean normalized SRTs for [the constant-frequency] Protocols 1 and 2 are statistically less than the mean normalized SRTs for [the varied-frequency] Protocols 3 and 4."
The conclusion they drew, verbatim: "Simultaneous frequency and amplitude modulation increases the SRT during closed-loop NMES control."
The "feels stronger but performs worse" pattern explained
Connecting the published research to the consumer experience produces a coherent picture. A fixed-frequency device, particularly one running at a relatively high constant frequency, can produce sharp, intense surface sensation in early sessions. It also fatigues the muscle faster — meaning contractions become less effective sooner within each session, and the cumulative conditioning effect across sessions plateaus earlier than with a varied-frequency architecture.
What the user observes is the divergence: impressive at first, less impressive over time. The harshness was real. The durability was not. By the time the user notices, they've been using a device for weeks that is doing decreasingly meaningful work on the muscle layer while still producing surface-level sensation.
This is not a failing of the user. It is a predictable consequence of the architecture. A device built around fixed-frequency stimulation will, on the published evidence, produce shorter effective performance windows than a varied-frequency alternative, even at the same nominal output specs.
Real Power. Smart Delivery.
The architectural distinction is what the phrase is built around. Real power is the amplitude and frequency band the device is operating in — both meaningful and capable of driving contraction. Smart delivery is the modulation pattern that varies frequency and amplitude continuously, so the muscle is engaged effectively at session one and at session fifty. A device with only the first half — real power, fixed delivery — produces the "feels strong, performs worse over time" pattern. A device with both produces sustained engagement that doesn't decline as the novelty wears off.
What to ask before buying
The diagnostic questions for buyers, ranked by predictive value:
- Is the operating frequency a single number or a range? A range implies modulation; a single number implies fixed.
- Is the modulation continuous or preset? Continuous waveform synthesis means the body cannot establish accommodation. Preset cycling between fixed waveforms still allows accommodation to compound on each individual preset.
- Are amplitude and frequency both modulated, or only frequency? Single-axis modulation is meaningfully better than fixed; dual-axis modulation is meaningfully better than single-axis.
- Does the device emphasize peak intensity in marketing, or sustained performance? Peak intensity is a session-1 spec. Sustained performance is the session-50 reality.
The first three questions will identify whether the architecture is built around the principles supported by the Downey work. The fourth is a tell on whether the brand understands the distinction or is selling a session-1 number to consumers who will eventually be making session-50 decisions.
What we are not claiming
For accuracy: the Downey 2011 study was conducted on the quadriceps of healthy subjects in the 20–40 Hz frequency range. PureLift devices operate at 1.37–1.73 kHz on facial musculature. The principle that modulated stimulation outperforms fixed-frequency stimulation for sustained performance transfers across these contexts — it is grounded in muscle physiology that does not depend on which muscle group is being stimulated — but the specific SRT numbers from the study are not a direct prediction of facial EMS session behavior. We cite the study for the architectural principle, not as a clinical endorsement of any specific consumer device.
For the device-specific claim: PureLift devices are engineered around continuously modulated stimulation, with the architectural intent of avoiding the fixed-frequency performance decline pattern documented in the Downey work. Whether that intent translates to the specific facial outcomes any individual user experiences depends on consistent use, technique, and the conductivity layer pairing.
The takeaway
Some EMS devices feel stronger but perform worse over time because their architecture is optimized for first-session sensation rather than sustained muscle engagement. The fix is not to dial back the power — it is to deliver the same power through a continuously modulated waveform, so the muscle stays in usable working condition session after session. Real power, smartly delivered. Not a positioning slogan. The architectural answer to a documented engineering trade-off.
The cleanest expression of the architecture in PureLift's lineup is the Pro+ with Activator Serum — full-amplitude EMS, dual-axis modulation across the kHz operating band, paired with the conductivity layer that lets the engineered waveform land where it should. For the related discussion on why peak specs underdetermine actual performance, see Raw Power vs. Usable Power. For the dose-cadence side of sustained performance, see The Smart-Delivery Dose Question.
Reference: Downey RJ, Bellman M, Sharma N, Wang Q, Gregory CM, Dixon WE. (2011). A novel modulation strategy to increase stimulation duration in neuromuscular electrical stimulation. Muscle & Nerve 44(3):382–387. DOI: 10.1002/mus.22058.